论文部分内容阅读
目的：观察早期应用替罗非班对冠状动脉粥样硬化性心脏病（ CAHD ）患者择期经皮穿刺冠状动脉介入治疗（ PCI ）效果的影响。方法 CAHD患者206例随机分成3组，围手术组（60例）于术前24 h给予替罗非班，起始剂量0.4μg·（ kg· min）-1，ivggt；30 min后，继续以0.1μg·（ kg· min）-1维持静脉滴注至PCI术后48 h。即刻组（56例）于PCI术开始时用药，治疗方案同上。对照组（90例）不用替罗非班。结果 PCI后，3组患者血小板聚集率较治疗前均明显下降（均P＜0.05），围手术期组和即刻组降低程度均明显高于对照组（均P＜0.05）；心肌梗死血栓溶解（TIMI）3级血流的患者，围手术期组升高程度较即刻组和对照更为显著（ P＜0.05）；对照组PCI术后并发症的发生率显著高于其他2组（均P＜0.05）。结论 PCI术早期用替罗非班安全有效。“,”Objective To evaluate the clinical efficacy of early stage u-sing of tirofiban in the treatment of coronary atherosclerotic herat disease ( CAHD) by percutaneous coronary intervention ( PCI).Methods Two hundred and six cases with CAHD were included in this study and divid-ed into 3 groups.The perioperation group with 60 cases [ tirofiban using 24-hour before PCI, 0.4 μg· (kg· min) -1],ivggt,30 min, followed by 0.1μg· (kg· min) -1, the immediate group with 56 cases( tirofiban using in the procedure of PCI ) and the control group with 90 case(with-out tirofiban ).The platelet aggregation , thrombolysis in myocardial in-farction ( TIMI ) improvement and major cardiovascular events were com-pared among the three groups.Results The platelet aggregation was sig-nificant decreased in the three groups compared with prior PCI ( both P<0.05 ) , with the immediate group and perioperation group much lower than control group ( P <0.05 ) .The grade 3 TIMI was significant in-creased after PCI ( both P<0.05 ) with immediate group and periopera-tion group much higher than control group ( P<0.05 ) .The complication incidence in the control group was higher than that in immediate and perioperation groups ( P<0.05 ).Conclusion Tirofiban is safe in the treatment of CAHD by PCI which can significantly inhibit platelet aggre-gation and reduce the risk of acute thrombosis.